thiazoles has been researched along with Biliary Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anania, FA; Miyahara, T; Motomura, K; Rippe, R; Schrum, L; Tsukamoto, H; Willson, TM; Xiong, S; Yee, HF | 1 |
| Mouri, H; Nakanuma, Y; Okai, T; Sawabu, N; Yamaguchi, Y | 1 |
2 other study(ies) available for thiazoles and Biliary Cirrhosis
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptors and hepatic stellate cell activation.
Topics: Animals; Cell Size; Cell Survival; Cells, Cultured; Collagen; DNA; Gene Expression Regulation; Liver; Liver Cirrhosis, Biliary; Liver Cirrhosis, Experimental; Male; Promoter Regions, Genetic; Prostaglandin D2; Protein Binding; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2000 |
Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis.
Topics: Autoantibodies; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis, Biliary; Middle Aged; Mitochondria; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |